Franck Bonnetain is a full Professor in epidemiology and biostatistics who received a master’s degree in clinical epidemiology from School of Public Health (Nancy, France). He obtained a PhD in public health with epidemiology and statistics specialties in 2005 as well asthe “Habilitation à diriger des recherches” (Professoral capability) in 2010. 



After working as epidemiologist for 3 years in Dijon for the “Institut de Veille Sanitaire”, he served as epidemiologist and biostatistician for the design, analyses and interpretation of clinical trials in Oncology. He was head of the methodology unit of French Federation of Digestive Cancerology (FFCD) and as head of methodology and quality of life unit of Georges François Leclerc Cancer care center from 2003 to 2012 (Dijon, France). Finally in September 2012 he was nominated as Professor in biostatistics, epidemiology, public health and quality of life in oncology at the university hospital of Besançon. He took the head of the methodology and quality of life in oncology unit.

In 2009, he launched and was co-founder of the French national clinical research plateform “Quality of life and cancer”.

He teaches statistics, epidemiology, methodology of clinical trials and quality of life in medical and pharmaceutical school as well as for master degree.


Research thematic:

 Definition, selection and validation of endpoints used in oncology clinical trials 

Health related quality of life and other Patient reported outcome in oncology

Design of clinical trials and epidemiological studies in oncology

Development of prognostic and predictive scoring system


Main areas of expertise:

- Methodology Statistics and clinical epidemiology

- Clinical trial and clinical research

- Quality of life

- Patient reported outcome

- Oncology

- Digestive Oncology

- Consensus methodology

- Supportive care


Main ongoing external collaborations:


- Full Member of EORTC QoL group since 2010 and board of Probe project since 2014

- Member of ARCAD Clinical Trials Program (http://arcad.marcelww.com/nos-actions/programmes-de-recherche/arcad-clinical-trials-program) and co-head of pancreatic cancer meta-analysis

- Head of DATECAN initiative (internal consensus for the definition of composite endpoints used in oncology clinical trials)

- Head of methodology of GERCOR since 2009 and member of PRODIGE group - Secretary of the AFSOS-UNICANCER French national supportive care group since 2013

- Referent Methodologist expert for GERICO (Geriatric oncology trials in France) and GI group of Unicancer

- Board of ANOCEF since 2010 (Association des neuro-oncologues d’expression française)

- Member of Cochrane lung cancer


Tools online

- Prognostic Score and Nomogram to Predict Overall Survival in Locally Advanced Pancreatic Cancer: The PROLAP score (mettre un lien qui renvoit sur l’outil)

Main publications

sample

Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for second-line...

Posted by : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurelia MEURISSE
Journal name : JNCI J Natl Cancer Inst

sample

AbstractBACKGROUND:The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has...

Posted by : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Journal name : Lancet Oncol

sample

AbstractPURPOSE:The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant...

Posted by : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Journal name : JCO

Latest publications

sample

Health-related quality of life (HRQOL) in cancer research is critical to more comprehensively evaluate patients’...

Posted by : Dr. Amélie ANOTA, Dr. Frederic FITENI, Pr. Franck BONNETAIN
Journal name : Journal of Clinical Oncology

sample

Measures of health-related quality of life (HRQOL) and other patient-reported outcomes generate important data in cancer...

Posted by : Pr. Franck BONNETAIN
Journal name : Lancet Oncology

sample

Abstract Background  The overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancer is a...

Posted by : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Journal name : BMC Cancer

sample

Abstract Background: Baseline prognostic biomarkers stratifying treatment strategies in first-line metastatic...

Posted by : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Journal name :

sample

In the Intergroupe Francophone de Cancérologie Thoracique 0501 trial the carboplatinpaclitaxel chemotherapy increased...

Posted by : Dr. Frederic FITENI, Dr. Amélie ANOTA, Pr. Franck BONNETAIN
Journal name : European Respiratory Journal

sample

ABSTRACTIntroduction: Intermediate endpoints are often used as primary endpoints instead of overall survival (OS) in...

Posted by : Dr. Frederic FITENI, Pr. Franck BONNETAIN
Journal name : Expert Review of Anticancer Therapy

sample

IMPORTANCE In locally advanced pancreatic cancer, the role of chemoradiotherapy is controversial and the efficacy of...

Posted by : Pr. Franck BONNETAIN
Journal name : JAMA

sample

AbstractBackground:Frailty is highly prevalent in elderly people. While significant progress has been made to...

Posted by : Dr. Dewi VERNEREY, Dr. Amélie ANOTA, Dr. Sophie PAGET-BAILLY, Mme. Audrey FOUBERT, Mme. Astrid POZET, Pr. Franck BONNETAIN
Journal name : BMC Geriatrics

sample

AbstractBACKGROUND:The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has...

Posted by : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Journal name : Lancet Oncol

OBJECTIVES: We conducted a prospective study approved by the local ethics committee to determine the impact of a...

Posted by : Pr. Franck BONNETAIN, Dr. Amélie ANOTA
Journal name : Annales pharmaceutiques françaises

Latest News

Latest tools

The R package QoLR allows to compute the scoring of main EORTC quality of life questionnaires and to perform the...

Posted by : Pr. Franck BONNETAIN, Dr. Amélie ANOTA

The R package QoLR allows to compute the scoring of main EORTC quality of life questionnaires and to perform the...

Posted by : Dr. Amélie ANOTA, Dr. Dewi VERNEREY, Dr. Amélie ANOTA, Pr. Franck BONNETAIN, Dr. Amélie ANOTA

The management of locally advanced pancreatic cancer (LAPC) patients remains controversial. Better discrimination for...

Posted by : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY, Dr. Dewi VERNEREY

MRQoL is a package that consists of three functions which allows us to calculate the Minimal Clinically Important...

Posted by : Pr. Franck BONNETAIN, Dr. Amélie ANOTA, Mr. Ahmad OUSMEN

The R package QoLR allows to compute the scoring of main EORTC quality of life questionnaires and to perform the...

Posted by : Dr. Amélie ANOTA, Dr. Dewi VERNEREY, Dr. Amélie ANOTA, Pr. Franck BONNETAIN, Dr. Amélie ANOTA

Communication from Pr Bonnetain at the 2nd EORTC Cancer Clinical Research Methodology Course for Patient Advocates,...

Posted by : Pr. Franck BONNETAIN

Posted by : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY

Discover Pr Bonnetain's keynote during the canceropôle IDF' seminar on rare tumours.Listen to the keynote here.Discover...

Posted by : Dr. Sophie PAGET-BAILLY, Pr. Franck BONNETAIN

Randomized Phase II Study of Weekly ABI-007plus Gemcitabine or Simplified LV5FU2 as FirstlineTherapy in Patients with...

Posted by : Pr. Franck BONNETAIN

2015-2017 © Copyright - UMQVC.org

Website by Pearlweb